| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.51 |
| 52 Week High | CN¥2.55 |
| 52 Week Low | CN¥1.33 |
| Beta | 0.62 |
| 11 Month Change | 3.08% |
| 3 Month Change | 2.31% |
| 1 Year Change | -36.28% |
| 33 Year Change | -77.73% |
| 5 Year Change | n/a |
| Change since IPO | -63.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 08HH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.5% | -1.3% | 0.9% |
| 1Y | -36.3% | -14.6% | 4.2% |
Return vs Industry: 08HH underperformed the German Pharmaceuticals industry which returned -14.6% over the past year.
Return vs Market: 08HH underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 08HH volatility | |
|---|---|
| 08HH Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 08HH has not had significant price volatility in the past 3 months.
Volatility Over Time: 08HH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 40,370 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 08HH fundamental statistics | |
|---|---|
| Market cap | €6.89b |
| Earnings (TTM) | €258.11m |
| Revenue (TTM) | €5.23b |
29.4x
P/E Ratio1.4x
P/S RatioIs 08HH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 08HH income statement (TTM) | |
|---|---|
| Revenue | CN¥40.69b |
| Cost of Revenue | CN¥21.50b |
| Gross Profit | CN¥19.19b |
| Other Expenses | CN¥17.18b |
| Earnings | CN¥2.01b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 47.16% |
| Net Profit Margin | 4.94% |
| Debt/Equity Ratio | 57.2% |
How did 08HH perform over the long term?
See historical performance and comparison